Results 21 to 30 of about 2,011 (166)

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

Parasites & Vectors, 2018
Background While the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of choice when this trial commenced.
Freddie Kansiime, Seraphine Adibaku, Charles Wamboga, Franklin Idi, Charles Drago Kato, Lawrence Yamuah, Michel Vaillant, Deborah Kioy, Piero Olliaro, Enock Matovu   +9 more
doaj   +1 more source

Heteroleptic Transition Metal Complexes of Eflornithine Hydrochloride Monohydrate: Synthesis, Characterization, in silico and in vitro Biological Studies

Journal of the Turkish Chemical Society, Section A: Chemistry, 2022
Incessant development of resistance to drugs by microorganisms remains a major setback associated with the currently available antibiotics, thereby making imperative a continuous search for alternative candidates with improved efficacy.
Yusuf AYİPO
doaj   +1 more source

Eflornithin [PDF]

pharma-kritik, 2009
Ein Ornithindekarboxylasehemmer, der in Form einer Crème bei Gesichtshirsutismus lokal appliziert werden kann. Bei etwa einem Drittel der behandelten Frauen lässt sich ein guter Erfolg erreichen, doch muss die Behandlung ständig weitergeführt werden.
openaire   +1 more source

Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases

Medical Sciences, 2018
The fluorinated ornithine analog α-difluoromethylornithine (DFMO, eflornithine, ornidyl) is an irreversible suicide inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme of polyamine biosynthesis.
Nicole LoGiudice, Linh Le, Irene Abuan, Yvette Leizorek, Sigrid C. Roberts   +4 more
doaj   +1 more source

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. [PDF]

PLoS Neglected Tropical Diseases, 2007
We report efficacy and safety outcomes from a prospective case series of 31 late-stage T.b. gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest ...
Francesco Checchi, Patrice Piola, Harriet Ayikoru, Florence Thomas, Dominique Legros, Gerardo Priotto   +5 more
doaj   +1 more source

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. [PDF]

PLoS Neglected Tropical Diseases, 2016
Trypanosoma brucei gambiense is the main causative agent of Human African Trypanosomiasis (HAT), also known as sleeping sickness. Because of limited alternatives and treatment toxicities, new therapeutic options are urgently needed for patients with HAT.
Frédéric-Antoine Dauchy, Mélanie Bonhivers, Nicolas Landrein, Denis Dacheux, Pierrette Courtois, Florian Lauruol, Sylvie Daulouède, Philippe Vincendeau, Derrick R Robinson   +8 more
doaj   +1 more source

Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030

Frontiers in Medicine, 2022
Human African Trypanosomiasis (HAT) is caused by unicellular flagellated protozoan parasites of the genus Trypanosoma brucei. The subspecies T. b. gambiense is mainly responsible for mostly chronic anthroponotic infections in West- and Central Africa ...
Andrés Álvarez-Rodríguez, Andrés Álvarez-Rodríguez, Bo-Kyung Jin, Magdalena Radwanska, Magdalena Radwanska, Stefan Magez, Stefan Magez, Stefan Magez   +7 more
doaj   +1 more source

The development of drugs for treatment of sleeping sickness: a historical review

Parasites & Vectors, 2010
Only four drugs are available for the chemotherapy of human African trypanosomiasis or sleeping sickness; Suramin, pentamidine, melarsoprol and eflornithine. The history of the development of these drugs is well known and documented. suramin, pentamidine
Steverding Dietmar
doaj   +1 more source

Principles of management of women with hirsutism – a dermatologist’s perspective

Przegląd Dermatologiczny, 2020
Hirsutism is a common clinical diagnosis defined by the presence of excess growth of terminal hair in androgen-sensitive areas. It affects 5–15% of women, often having a significant impact on their daily functioning. Hirsutism is mainly caused by ovarian
Dominik Mikiel, Barbara Olszewska, Adriana Polańska, Zygmunt Adamski, Ryszard Żaba, Aleksandra Dańczak-Pazdrowska   +5 more
doaj   +1 more source

Potentials of curcumin against polycystic ovary syndrome: Pharmacological insights and therapeutic promises

Heliyon, 2023
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women (4%–20%) when the ovaries create abnormally high levels of androgens, the male sex hormones that are typically present in women in trace amounts.
Tanzina Akter, Md. Sarwar Zahan, Nafisa Nawal, Md. Hasanur Rahman, Tayyabatun Nur Tanjum, Kazi Ifthi Arafat, Akhi Moni, Mohammad Nazrul Islam, Md Jamal Uddin   +8 more
doaj   +1 more source